Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · April 21, 2022

Survival Outcomes With De-Escalated Neoadjuvant Pertuzumab Plus Trastuzumab With or Without Weekly Paclitaxel in HER2+/HR− Early Breast Cancer

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
Lancet Oncol 2022 Apr 08;[EPub Ahead of Print], U Nitz, O Gluz, M Graeser, M Christgen, S Kuemmel, EM Grischke, M Braun, D Augustin, J Potenberg, K Krauss, C Schumacher, H Forstbauer, T Reimer, A Stefek, HH Fischer, E Pelz, C Zu Eulenburg, R Kates, R Wuerstlein, HH Kreipe, N Harbeck

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading